Literature DB >> 20414942

Differential diagnosis of liver diseases using serum biomarkers.

D Cujic1, S Golubovic, Z Bojic-Trbojevic, N Ilic, I Baricevic, O Nedic.   

Abstract

PURPOSE: Many human blood proteins are synthesised in the liver. Their serum levels may decrease or increase due to liver disorders and some of them serve as useful biomarkers. Determination of serum concentration of different biomarkers has important role in diagnosis of liver diseases and in monitoring the course of disease. In this work 3 serum markers associated with liver disorders were compared. The aim was to assess whether these biomarkers exhibit specific distribution pattern in different types of liver disease: liver neoplasia (primary hepatocellular carcinoma [HC] or metastatic liver disease [MLD] from colon cancer), viral hepatitis C (HCV) and the parasitic infection echinococcosis.
METHODS: Serum concentrations of alpha-fetoprotein (AFP), ferritin and insulin-like growth factor I (IGF-I) were determined in patients with liver disease and compared between patient groups and with healthy persons.
RESULTS: Serum AFP and ferritin levels exhibited similar pattern of change in patients with liver neoplasia or HCV, and concentrations of these 2 markers were significantly increased compared to the control group (p < 0.01 in each case). On the other hand, the concentration of IGF-I was significantly decreased in patients with liver neoplasia or echinococcosis compared to the control group (p < 0.05 for both). The concentration of IGF-I was significantly lower and the concentration of ferritin significantly higher in patients with HC than in patients with MLD from colorectal cancer (p < 0.01 for both).
CONCLUSION: The results have shown that each hepatic pathology studied exhibited specific profile of the analysed set of biomarkers. Therefore, the simultaneous determination of the 3 mentioned biomarkers may help in differential diagnosis of liver diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414942

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  2 in total

1.  Screening, identification of prostate cancer urinary biomarkers and verification of important spots.

Authors:  Huijun Zhao; Xuhong Zhao; Ting Lei; Man Zhang
Journal:  Invest New Drugs       Date:  2019-01-04       Impact factor: 3.850

2.  Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jing Wang; Yu-Chuan Li; Min Deng; Hai-Yin Jiang; Li-Hua Guo; Wen-Juan Zhou; Bing Ruan
Journal:  Oncotarget       Date:  2017-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.